Which Peptides Are Returning to Legal Compounding (2026)?

In April 2026, the FDA removed 12 peptides — including BPC-157, TB-500, KPV, and MOTS-c — from the 503A "Category 2" safety-concern list and scheduled a July 23–24, 2026 advisory committee meeting to weigh adding several to the eligible-for-compounding list. Removal alone does not make compounding legal; formal rulemaking must follow.

Peptides legal compounding 2026 at a glance

• What changed: On April 15, 2026, the FDA gave notice it would remove 12 peptide bulk drug substances from Category 2 of the 503A bulks list, effective ~7 days later, because the original nominations were withdrawn.
• The 12 removed: BPC-157, Cathelicidin LL-37, Dihexa, Emideltide (DSIP), Epitalon, GHK-Cu (injectable), KPV, PEG-MGF, Melanotan II, MOTS-c, Semax, and TB-500 (thymosin beta-4 fragment).
• Next milestone: July 23–24, 2026 Pharmacy Compounding Advisory Committee (PCAC) meeting (FDA docket FDA-2025-N-6895) on whether to add 7 of these to the eligible list.
• The catch: Removal from Category 2 is not authorization to compound. A substance must reach Category 1 (or the final 503A bulks list) through notice-and-comment rulemaking first.
• Status of all 12: Not FDA-approved; no USP/NF monograph; in regulatory limbo pending PCAC and rulemaking.

What actually changed in April 2026?

On April 15, 2026, the FDA announced it would remove 12 peptide bulk drug substances from Category 2 of its interim Section 503A bulk drug substances list, with the change taking effect roughly seven days later. The agency's stated reason was procedural: the nominators who had originally submitted these substances for evaluation had withdrawn their nominations, so the agency removed them rather than continuing to list them as raising significant safety concerns (FDA, Federal Register notice, docket FDA-2025-N-6895, April 2026).

To understand why this matters, you need the structure of the 503A bulks list. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a state-licensed pharmacist may compound a drug from a bulk substance only if that substance meets one of three conditions: it complies with an applicable United States Pharmacopeia (USP) or National Formulary (NF) monograph, it is a component of an FDA-approved drug, or it appears on FDA's 503A bulks list (FDA, "Bulk Drug Substances Used in Compounding Under Section 503A"). While FDA finalizes that list, it maintains an interim policy sorting nominated substances into categories:

• Category 1 — substances FDA may evaluate further and has not identified as raising significant safety risks; FDA generally exercises enforcement discretion, meaning pharmacies can compound with them under 503A conditions.
• Category 2 — substances FDA preliminarily determined raise significant safety concerns; this designation has historically supported enforcement action.

So the 12 peptides moved out of the "significant safety concern" bucket. That is a meaningful shift in tone after years of warning letters and import alerts. But — and this is the part most headlines get wrong — it did not move them into the bucket where compounding is permitted.

Legal status varies by jurisdiction; consult a lawyer for binding advice.

Does removal from Category 2 make these peptides legal to compound?

No. This is the single most important point in this article. Removal from Category 2 does not render a bulk drug substance eligible for compounding under Section 503A, and it does not bring the substance within FDA's interim enforcement-discretion policy (FDA, Federal Register notice, docket FDA-2025-N-6895, 2026; Frier Levitt regulatory analysis, 2026).

In practical terms, the 12 removed peptides now sit in a regulatory gray zone. None is FDA-approved. None has a recognized USP or NF monograph. None is currently a component of an approved drug. To become lawfully compoundable, a substance must reach Category 1 or the finalized 503A bulks list — and FDA can only place a substance there through formal notice-and-comment rulemaking, a process that follows (and is informed by) the advisory committee's review.

The advisory committee itself is non-binding. The PCAC recommends; it does not decide. Even a unanimous "add it to the list" recommendation would still require FDA to agree and then complete rulemaking before a pharmacy could legally compound the substance.

So the honest 2026 answer to "are these peptides legal to compound now?" is: not yet, and possibly not at all, depending on how PCAC and rulemaking play out.

Which peptides go before the PCAC in July 2026?

The FDA scheduled a Pharmacy Compounding Advisory Committee meeting for July 23–24, 2026 to consider whether to add several peptides to the 503A bulks list (FDA, "July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee"; docket FDA-2025-N-6895). The agenda splits across two days:

July 23, 2026:

• BPC-157 (free base / acetate)
• KPV (free base / acetate)
• TB-500 / thymosin beta-4 fragment (free base / acetate)
• MOTS-c (free base / acetate)

July 24, 2026:

• Emideltide, also called delta sleep-inducing peptide / DSIP (free base / acetate)
• Semax (free base / acetate)
• Epitalon (free base / acetate)

For each nominated substance, the nominators are invited to give a short presentation, and the public docket is open for written comment (comments received on or before July 9, 2026 are provided to the committee; later comments through July 22, 2026 are taken into consideration) (FDA, PCAC meeting notice, 2026). This is the formal evidentiary record FDA will weigh.

Note that the 7 peptides headed to PCAC are a subset of the 12 removed from Category 2. The remaining five — Cathelicidin LL-37, Dihexa, Epitalon's cousins aside, GHK-Cu (injectable), PEG-MGF, and Melanotan II — were removed from Category 2 but are not on the July agenda, leaving their path even less defined.

What does the research actually show for these peptides?

A regulatory nomination is not the same as proven human efficacy. Most of these peptides are supported primarily by preclinical (cell and animal) data, with limited or no large-scale human trials. Here is the evidence level for the most-discussed candidates.

BPC-157. A synthetic 15-amino-acid peptide derived from a protein in gastric juice. In a cell and animal study, BPC-157 accelerated tendon-fibroblast outgrowth, increased cell survival under oxidative stress, and promoted fibroblast migration in a dose-dependent manner (Chang et al., 2011, J Appl Physiol 110(3):774–780). Research in animal models suggests BPC-157 may support tendon and gastrointestinal tissue repair; controlled human efficacy data remain limited. See our BPC-157 complete guide and BPC-157 legal status explainer.

MOTS-c. A 16-amino-acid mitochondrial-derived peptide. In mice, MOTS-c regulated insulin sensitivity and metabolic homeostasis via the AMPK pathway and reduced diet-induced obesity and insulin resistance (Lee et al., 2015, Cell Metab 21(3):443–454). Research in animal models suggests MOTS-c may support metabolic regulation; human data are early.

KPV. A three-amino-acid fragment of alpha-melanocyte-stimulating hormone. In experimental colitis models, PepT1-mediated uptake of KPV reduced intestinal inflammation by inhibiting NF-κB and MAP-kinase signaling and lowering pro-inflammatory cytokines (Dalmasso et al., 2008, Gastroenterology 134(1):166–178). Research in animal models suggests KPV may support a reduced inflammatory response; human trials are lacking.

TB-500 (thymosin beta-4 fragment). Thymosin beta-4 is the primary G-actin-sequestering peptide in mammalian cells and has been studied for roles in cell migration, angiogenesis, and wound repair in preclinical models. Semax and Epitalon are largely supported by Russian-language clinical and preclinical literature; Semax is an ACTH(4–10) analog approved as a prescription drug in Russia but not in the United States. For all of these, human evidence in U.S.-recognized trials is limited — a point PCAC will likely scrutinize.

Consult your healthcare provider before starting any peptide protocol. None of these peptides is FDA-approved, and "removed from Category 2" is a regulatory status, not a safety endorsement.

How could the 2026–2027 timeline play out?

The realistic sequence, based on the published schedule, looks like this:

1. Now through July 2026 — public docket open; nominators and the public submit evidence (FDA docket FDA-2025-N-6895).
2. July 23–24, 2026 — PCAC hears presentations and votes on recommendations for the 7 agenda peptides.
3. After the meeting — FDA reviews the recommendation (non-binding) and the full record.
4. Notice-and-comment rulemaking — if FDA decides to add any peptide to the 503A bulks list (Category 1 / final list), it must publish a proposed rule, take public comment, and issue a final rule. This typically takes many months to years.
5. A possible second PCAC meeting — reporting indicates additional review could occur into early 2027.

Until a peptide actually reaches the final 503A bulks list (or Category 1) through that process, compounding it remains outside FDA's enforcement-discretion policy. Treat any vendor or clinic claiming these peptides are "now legal to compound in 2026" as a sourcing red flag. For evaluating sellers, see our peptide sourcing guide; for how rules differ where you live, see peptide legality by state.

Frequently asked questions

Q: Are BPC-157 and TB-500 legal to buy and use in 2026? A: BPC-157 and TB-500 were removed from the FDA's 503A Category 2 list in April 2026, but neither is FDA-approved and neither is currently eligible for compounding under Section 503A. Removal from Category 2 does not authorize compounding; a substance must reach Category 1 or the final 503A bulks list through formal rulemaking first. Many products sold online are labeled "for research use only," which is a sourcing and legal red flag. Legal status varies by jurisdiction. Consult a licensed healthcare provider and, for binding guidance, an attorney.

Q: What is the difference between Category 1 and Category 2 on the 503A bulks list? A: Under FDA's interim 503A policy, Category 1 contains nominated bulk substances that FDA has not identified as raising significant safety risks; FDA generally exercises enforcement discretion, so compounding pharmacies can use them under Section 503A conditions. Category 2 contains substances FDA preliminarily determined raise significant safety concerns, which has historically supported enforcement action. The 12 peptides removed in April 2026 moved out of Category 2 but were not placed in Category 1, leaving them ineligible for compounding for now.

Q: What is the PCAC and why does the July 2026 meeting matter? A: The Pharmacy Compounding Advisory Committee (PCAC) is an FDA advisory body that reviews bulk drug substances nominated for the 503A compounding list and makes recommendations to the agency. At the July 23–24, 2026 meeting (FDA docket FDA-2025-N-6895), it will weigh evidence on BPC-157, KPV, TB-500, MOTS-c, Emideltide/DSIP, Semax, and Epitalon. The committee's recommendations are non-binding; FDA still must agree and complete rulemaking before any peptide becomes legally compoundable.

Q: Which 12 peptides were removed from Category 2 in April 2026? A: According to the FDA notice and regulatory analyses, the 12 are BPC-157, Cathelicidin LL-37, Dihexa, Emideltide (DSIP), Epitalon, GHK-Cu (injectable routes), KPV, PEG-MGF (pegylated mechano growth factor), Melanotan II, MOTS-c, Semax, and TB-500 (thymosin beta-4 fragment). They were removed because the original nominations were withdrawn, not because FDA endorsed their safety or efficacy. Seven of the twelve are on the July 2026 PCAC agenda.

Q: Does "removed from Category 2" mean a peptide is now safe? A: No. Removal from Category 2 is a procedural and regulatory status, not a safety endorsement. It reflects that the nominations were withdrawn and FDA is no longer listing the substances as raising significant safety concerns on the interim list. None of the 12 peptides is FDA-approved, and most are supported mainly by animal and cell studies rather than large human trials. Consult your healthcare provider before considering any peptide.

Q: When could these peptides actually become legal to compound? A: There is no guaranteed date. After the July 2026 PCAC meeting, FDA must decide whether to propose adding any peptide to the 503A bulks list, then complete notice-and-comment rulemaking, which can take months to years. Some reporting suggests additional review could extend into 2027. Until a peptide reaches Category 1 or the final 503A bulks list, compounding it stays outside FDA's enforcement-discretion policy. Legal status varies by jurisdiction.

Q: Are these peptides available through 503B outsourcing facilities? A: Not on this basis. A 503B outsourcing facility may compound from a bulk substance only if it appears on the 503B bulks list (substances for which FDA has found a clinical need) or the drug is on FDA's shortage list. The April 2026 action concerned the 503A list, not the 503B clinical-need list, so it does not by itself open a 503B pathway for these peptides. Consult your healthcare provider and pharmacy for current status.

References

1. U.S. Food and Drug Administration. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. FDA Advisory Committee Calendar. https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
2. U.S. Food and Drug Administration / Federal Register. Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments — Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List. Docket FDA-2025-N-6895, April 16, 2026. https://www.federalregister.gov/documents/2026/04/16/2026-07361/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request
3. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
4. Chang C-H, Tsai W-C, Lin M-S, Hsu Y-H, Pang J-H. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985). 2011;110(3):774–780. PMID: 21030672. DOI: 10.1152/japplphysiol.00945.2010. https://pubmed.ncbi.nlm.nih.gov/21030672/
5. Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443–454. PMID: 25738459. DOI: 10.1016/j.cmet.2015.02.009. https://pubmed.ncbi.nlm.nih.gov/25738459/
6. Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166–178. PMID: 18061177. DOI: 10.1053/j.gastro.2007.10.026. https://pubmed.ncbi.nlm.nih.gov/18061177/
7. Frier Levitt. FDA to Remove 12 Popular Peptides from the Category 2 "Do Not Compound" List (regulatory analysis). 2026. https://www.frierlevitt.com/articles/fda-peptides-do-not-compound-list-update-2026/